METHOD IEC Electromagnetic field Sample Clauses

METHOD IEC Electromagnetic field. The VAS/AS shall undergo the basic test. It shall be subjected to the electromagnetic field test described in IEC Publication 839-1-3-1998 test A-13 with a frequency range from 20 to 1000 MHz, and for a field strength level of 30 V/m. In addition, the VAS/AS shall be subjected to the electrical transient conducted and coupled tests described in the International Standard ISO 7637 Parts 1:1990, 2:1990 and 3:1995, as appropriate. Electrical disturbance from electrostatic discharges The VAS/AS shall undergo the basic test. It shall be subjected to testing for immunity against electrostatic discharge as described in either EN 00000-0-0, or ISO/TR 10605-1993, at the manufacturer's choice. Radiated emissions The VAS/AS shall be subjected to testing for the suppression of radio frequency interference according to tests prescribed in Regulation No. 10, 02 series of amendments and according to tests method described in annexes 4 and 5 for vehicles and annexes 7 and 8 for a separate technical unit. E/ECE/TRANS/505 Regulation No. 116 page 74 Annex 10 Annex 10 SPECIFICATIONS FOR MECHANICAL KEY SWITCHES
AutoNDA by SimpleDocs
METHOD IEC Electromagnetic field. The VAS/AS device shall undergo the basic test. It shall be subjected to the electromagnetic field test described in IEC Publication 839-1-3-1998 test A-13 with a frequency range from 20 to 1000 MHz, and for a field strength level of 30 V/m. In addition, the VAS/AS device shall be subjected to the electrical transient conducted and coupled tests described in the International Standard ISO 7637 Parts 1:1990, 2:1990 and 3:1995, as appropriate. Electrical disturbance from electrostatic discharges The VAS/AS device shall undergo the basic test. It shall be subjected to testing for immunity against electrostatic discharge as described in either EN 00000-0-0, or ISO/TR 10605-1993, at the manufacturer's choice. Radiated emissions The VAS/AS device shall be subjected to testing for the suppression of radio frequency interference according to the technical prescriptions and transitional provisions of Regulation No. 10, 04 series of amendments and according to tests method described in Annexes 4 and 5 for vehicles and Annexes 7 and 8 for a separate technical unit. E/ECE/324 E/ECE/TRANS/505 Regulation No. 116 page 36 Annex 10

Related to METHOD IEC Electromagnetic field

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Unbundled Channelization (Multiplexing) 5.7.1 To the extent NewPhone is purchasing DS1 or DS3 or STS-1 Dedicated Transport pursuant to this Agreement, Unbundled Channelization (UC) provides the optional multiplexing capability that will allow a DS1 (1.544 Mbps) or DS3 (44.736 Mbps) or STS-1 (51.84 Mbps) Network Elements to be multiplexed or channelized at a BellSouth central office. Channelization can be accomplished through the use of a multiplexer or a digital cross-connect system at the discretion of BellSouth. Once UC has been installed, NewPhone may request channel activation on a channelized facility and BellSouth shall connect the requested facilities via COCIs. The COCI must be compatible with the lower capacity facility and ordered with the lower capacity facility. This service is available as defined in NECA 4.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Diagnosis For a condition to be considered a covered illness or disorder, copies of laboratory tests results, X-rays, or any other report or result of clinical examinations on which the diagnosis was based, are required as part of the positive diagnosis by a physician.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Influenza Vaccination The parties agree that influenza vaccinations may be beneficial for patients and employees. Upon a recommendation pertaining to a facility or a specifically designated area(s) thereof from the Medical Officer of Health or in compliance with applicable provincial legislation, the following rules will apply:

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

Time is Money Join Law Insider Premium to draft better contracts faster.